Femasys to Exhibit at the Annual AAGL 2024 Global Conference
Femasys (NASDAQ: FEMY) announces its participation in the AAGL 2024 Annual Global Conference, scheduled for November 16-19 in New Orleans, Louisiana. The biomedical company will exhibit at booth #902, showcasing its late-stage clinical development product FemBloc® along with other commercially available solutions. The conference focuses on gynecological surgery and provides Femasys an opportunity to present its portfolio of in-office, accessible therapeutic and diagnostic products designed to address unmet needs in women's healthcare.
Femasys (NASDAQ: FEMY) annuncia la sua partecipazione alla Conferenza Globale Annuale AAGL 2024, in programma dal 16 al 19 novembre a New Orleans, Louisiana. L'azienda biomedica esporrà allo stand #902, presentando il suo prodotto in fase avanzata di sviluppo clinico FemBloc® insieme ad altre soluzioni disponibili sul mercato. La conferenza si concentra sulla chirurgia ginecologica e offre a Femasys l'opportunità di presentare il proprio portafoglio di prodotti terapeutici e diagnostici accessibili per l'ufficio, progettati per affrontare le esigenze insoddisfatte nella salute delle donne.
Femasys (NASDAQ: FEMY) anuncia su participación en la Conferencia Global Anual AAGL 2024, programada del 16 al 19 de noviembre en Nueva Orleans, Luisiana. La empresa biomédica exhibirá en el stand #902, mostrando su producto en desarrollo clínico de última etapa FemBloc® junto con otras soluciones disponibles comercialmente. La conferencia se centra en la cirugía ginecológica y proporciona a Femasys la oportunidad de presentar su portafolio de productos terapéuticos y diagnósticos accesibles diseñados para abordar las necesidades no satisfechas en la salud de las mujeres.
Femasys (NASDAQ: FEMY)는 11월 16일부터 19일까지 루이지애나주 뉴올리언스에서 열리는 AAGL 2024 연례 글로벌 컨퍼런스에 참가한다고 발표했습니다. 이 생명공학 회사는 부스 #902에서 전시하며, 임상 개발이 후기 단계에 있는 제품 FemBloc®와 기타 상업적으로 사용 가능한 솔루션을 선보일 예정입니다. 이 컨퍼런스는 부인과 수술에 초점을 맞추고 있으며, Femasys가 여성 건강에서 충족되지 않은 요구를 해결하기 위해 설계된 사무실 수용 가능 치료 및 진단 제품 포트폴리오를 발표할 수 있는 기회를 제공합니다.
Femasys (NASDAQ: FEMY) annonce sa participation à la Conférence Globale Annuelle AAGL 2024, prévue du 16 au 19 novembre à La Nouvelle-Orléans, Louisiane. L'entreprise biomédicale exposera au stand #902, mettant en avant son produit en développement clinique avancé FemBloc® ainsi que d'autres solutions disponibles sur le marché. La conférence se concentre sur la chirurgie gynécologique et offre à Femasys l'occasion de présenter son portefeuille de produits thérapeutiques et diagnostiques accessibles en cabinet, conçus pour répondre aux besoins non satisfaits en matière de santé des femmes.
Femasys (NASDAQ: FEMY) gibt seine Teilnahme an der AAGL 2024 Jahresglobalen Konferenz bekannt, die vom 16. bis 19. November in New Orleans, Louisiana, stattfinden wird. Das biomedizinische Unternehmen wird am Stand #902 ausstellen und sein klinisches Entwicklungsprodukt FemBloc® sowie andere kommerziell verfügbare Lösungen präsentieren. Die Konferenz konzentriert sich auf gynäkologische Chirurgie und bietet Femasys die Möglichkeit, sein Portfolio an zugänglichen therapeutischen und diagnostischen Produkten für das Büro, die entwickelt wurden, um ungedeckte Bedürfnisse im Gesundheitswesen für Frauen anzugehen, vorzustellen.
- None.
- None.
Premier conference focused on gynecological surgery
ATLANTA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Association of Gynecologic Laparoscopists (AAGL) 2024 Annual Global Conference, being held November 16-19 in New Orleans, Louisiana. The Company will be showcasing its product candidate in late-stage clinical development, FemBloc®, as well as its other commercially available solutions at booth #902.
About AAGL
AAGL is the largest medical society focused on gynecologic surgery, with an international membership of over 7,500 physicians and healthcare providers committed to advancing minimally invasive gynecologic surgery (MIGS). Its mission is to elevate the quality and safety of health care for women through excellence in clinical practice, education, research, innovation, and advocacy. AAGL’s Annual Global Congress is the premier scientific program that provides the world’s finest gynecologic surgeons with the latest education and best practices in MIGS. To learn more about AAGL 2024, visit the organization’s website.
About FemBloc
FemBloc® is a first-of-its-kind, nonsurgical, non-implant, in-office solution in its late-stage of clinical development for permanent birth control. It is intended to be a safer option for women estimated at approximately half the cost of the long-standing surgical alternative by eliminating the need for anesthesia, incisions, and permanent implants. FemBloc has the potential to offer women a convenient, accessible, and reliable option for those seeking permanent birth control. For over 100 years there has been stagnant innovation for permanent birth control which could lead to a
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasys.com
Media:
Kati Waldenburg
Media@femasys.com
FAQ
When is Femasys (FEMY) exhibiting at the AAGL 2024 Global Conference?
What products will Femasys (FEMY) showcase at the AAGL 2024 Conference?
Where is Femasys (FEMY) booth located at the AAGL 2024 Conference?
